drugset / Trial / NCT06484920
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase II single-center open label trial of the combination of ATRA and pembrolizumab treatment in patients with histologically proven, relapsed or refractory Hodgkin Lymphoma or B-Non-Hodgkin-lymphoma.
Timeline
- Start
- 2024-11-18
- Primary completion
- 2027-12
- Completion
- 2029-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |
| Subject | Tretinoin | Small molecule | 150 mg/m2 | Oral |